1
|
Civallero M, Schroers-Martin JG, Horwitz S, Manni M, Stepanishyna Y, Cabrera ME, Vose J, Spina M, Hitz F, Nagler A, Montoto S, Chiattone C, Skrypets T, Perez Saenz MA, Priolo G, Luminari S, Lymboussaki A, Pavlovsky A, Marino D, Liberati M, Trotman J, Mannina D, Federico M, Advani R. Long-term outcome of peripheral T-cell lymphomas: Ten-year follow-up of the International Prospective T-cell Project. Br J Haematol 2024. [PMID: 38532575 DOI: 10.1111/bjh.19433] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Revised: 02/27/2024] [Accepted: 03/16/2024] [Indexed: 03/28/2024]
Abstract
Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of haematological cancers with generally poor clinical outcomes. However, a subset of patients experience durable disease control, and little is known regarding long-term outcomes. The International T-cell Lymphoma Project (ITCLP) is the largest prospectively collected cohort of patients with PTCLs, providing insight into clinical outcomes at academic medical centres globally. We performed a long-term outcome analysis on patients from the ITCLP with available 10-year follow-up data (n = 735). The overall response rate to first-line therapy was 68%, while 5- and 10-year overall survival estimates were 49% and 40% respectively. Most deaths occurred prior to 5 years, and for patients alive at 5 years, the chance of surviving to 10 years was 84%. However, lymphoma remained the leading cause of death in the 5- to 10-year period (67%). Low-risk International Prognostic Index and Prognostic Index for T-cell lymphoma scores both identified patients with improved survival, while in multivariate analysis, age >60 years and Eastern Cooperative Oncology Group performance status 2-4 were associated with inferior outcomes. The favourable survival seen in patients achieving durable initial disease control emphasizes the unmet need for optimal front-line therapeutic approaches in PTCLs.
Collapse
Affiliation(s)
- M Civallero
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - J G Schroers-Martin
- Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA
| | - S Horwitz
- Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
| | - M Manni
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, Modena, Italy
| | - Y Stepanishyna
- Department of Bone Marrow Transplant, National Cancer Institute, Kyiv, Ukraine
| | - M E Cabrera
- Sección Hematología, Hospital del Salvador, Universidad de Chile, Santiago, Chile
| | - J Vose
- Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - M Spina
- Division of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
| | - F Hitz
- Department of Oncology/Haematology, The Swiss Group for Clinical Cancer Research, Cantonal Hospital, St Gallen, Switzerland
| | - A Nagler
- Department of Bone Marrow Transplantation, Tel-Aviv University, Tel-Aviv, Israel
| | - S Montoto
- Department of Haemato-Oncology, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK
| | - C Chiattone
- Higienopolis and Santa Casa Medical School of Sao Paulo, Samaritano Hospital, São Paulo, Brazil
| | - T Skrypets
- Hematology and Cell Therapy Department, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - M A Perez Saenz
- Department of Hematology, Health Research Institute IIS-FJD, Fundacion Jimenez Diaz University Hospital, Madrid, Spain
| | - G Priolo
- Hematology 2, San Giovanni Battista Hospital and University, Turin, Italy
| | - S Luminari
- Hematology Unit, Azienda USL-IRCCS Reggio Emilia, Reggio Emilia, Italy
| | - A Lymboussaki
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - A Pavlovsky
- Fundación para Combatir la Leucemia (FUNDALEU), Centro de Hematología Pavlovsky, Buenos Aires, Argentina
| | - D Marino
- Department of Oncology, Oncology 1 Unit, Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
| | - M Liberati
- A.O. Santa Maria, S.C. di Oncoematologia di Terni, Università Degli Studi di Perugia, Perugia, Italy
| | - J Trotman
- Concord Repatriation General Hospital, University of Sydney, Concord, New South Wales, Australia
| | - D Mannina
- Hematology Unit, AO Papardo, Messina, Italy
| | - M Federico
- CHIMOMO Department, University of Modena and Reggio Emilia, Modena, Italy
| | - R Advani
- Division of Oncology, Department of Medicine, Stanford University, Stanford, California, USA
| |
Collapse
|
2
|
Franceschini D, Greto D, Dicuonzo S, Navarria F, Federico M, La Vecchia M, Sangalli C, Allajbej A, Di Cristina L, Mazzola R, Pontoriero A, Montesi G, Navarria P, Baldaccini D, Clerici E, Lo Faro L, Franzese C, Di Biase S, Pergolizzi S, Alongi F, Bignardi M, Fazio I, Mascarin M, Jereczek-Fossa BA, Livi L, Scorsetti M. Oligometastatic sarcoma treated with Curative intent Ablative Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association of Radiotherapy and clinical Oncology). Radiother Oncol 2024; 191:110078. [PMID: 38163485 DOI: 10.1016/j.radonc.2023.110078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 12/18/2023] [Accepted: 12/29/2023] [Indexed: 01/03/2024]
Abstract
BACKGROUND AND PURPOSE Stereotactic Ablative Radiotherapy (SABR) is emerging as a valid alternative to surgery in the oligometastatic setting in soft tissue sarcomas (STS), although robust data are lacking. The aim of this study is to evaluate toxicity and efficacy of SABR in oligometastatic STS. MATERIALS AND METHODS This is a retrospective multicenter study including adult patients affected by stage IV STS, treated with SABR for a maximum of 5 cranial or extracranial metastases in up to 3 different organs. SABR was delivered with ablative purposes. Study endpoints were overall survival (OS), local control (LC), distant progression free survival (DPFS), time to polymetastatic progression (TTPP), time to new systemic therapy (TTNS) and toxicity. RESULTS From 10 Italian RT centers, 138 patients (202 metastases) treated between 2010 and 2022 were enrolled in the study. Treatment was generally well tolerated, no acute or late toxicity ≥ G3 was recorded. Median follow up was 42.5 months. Median OS was 39.7 months. Actuarial OS at 1 and 2 years was 91.5 % and 72.7 %. Actuarial LC at 1 and 2 years was 94.8 % and 88.0 %. Median DPFS was 9.7 months. Actuarial DPFS at 1 and 2 years was 40.8 % and 19.4 %. CONCLUSION SABR is a safe and effective approach for the treatment of oligometastatic sarcoma. One out of 5 patients is free of progression at 2-years.
Collapse
Affiliation(s)
- D Franceschini
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
| | - D Greto
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy
| | - S Dicuonzo
- Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - F Navarria
- Radiation Oncology Department, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
| | - M Federico
- Radiotherapy Unit, Casa di Cura Macchiarella, Palermo, Italy
| | - M La Vecchia
- Radiotherapy Unit, Casa di Cura Macchiarella, Palermo, Italy
| | - C Sangalli
- Department of Radiation Therapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Allajbej
- Department of Radiation Therapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - L Di Cristina
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
| | - R Mazzola
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37034, Negrar Di Valpolicella, Verona, Italy
| | - A Pontoriero
- Radiation Oncology Unit, A.O.U. "G. Martino", Messina, Italy; Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy
| | - G Montesi
- Radiation Therapy Unit ULSS5 Veneto, Rovigo, Italy
| | - P Navarria
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - D Baldaccini
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - E Clerici
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy
| | - L Lo Faro
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
| | - C Franzese
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
| | - S Di Biase
- Radiation Therapy Unit ULSS5 Veneto, Rovigo, Italy
| | - S Pergolizzi
- Radiation Oncology Unit, A.O.U. "G. Martino", Messina, Italy; Department of Biomedical, Dental Science and Morphological and Functional Images, University of Messina, Messina, Italy
| | - F Alongi
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Cancer Care Center, 37034, Negrar Di Valpolicella, Verona, Italy; University of Brescia, Brescia, Italy
| | - M Bignardi
- Department of Radiation Oncology, Fondazione Poliambulanza, 25124 Brescia, Italy
| | - I Fazio
- Radiotherapy Unit, Casa di Cura Macchiarella, Palermo, Italy
| | - M Mascarin
- Radiation Oncology Department, IRCCS Centro di Riferimento Oncologico, Aviano, Italy; AYA Oncology and Pediatric Radiotherapy Unit, IRCCS Centro di Riferimento Oncologico, Aviano, Italy
| | - B A Jereczek-Fossa
- Division of Radiotherapy, IEO, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy
| | - L Livi
- Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy; Department of Biomedical, Experimental and Clinical Sciences, Serio" University of Florence, Florence, Italy
| | - M Scorsetti
- Department of Radiotherapy and Radiosurgery, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090 Milan, Italy
| |
Collapse
|
3
|
Cuccia F, Pastorello E, Franzese C, Belgioia L, Bignardi M, Federico M, Figlia V, Giaj Levra N, Badellino S, Borghetti P, Marvaso G, Montesi G, Pontoriero A, Fazio I, Ferrera G, Alongi F, Scorsetti M. Stereotactic Body Radiotherapy for Spine Oligometastases: A Multicentre Retrospective Study From the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Clin Oncol (R Coll Radiol) 2023; 35:794-800. [PMID: 37714793 DOI: 10.1016/j.clon.2023.09.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2023] [Revised: 07/26/2023] [Accepted: 09/04/2023] [Indexed: 09/17/2023]
Abstract
AIM To evaluate the efficacy of stereotactic body radiotherapy (SBRT) for spine oligometastases. MATERIALS AND METHODS This was a multicentre retrospective study of a series of patients who received SBRT for spine oligometastases. The efficacy of SBRT was evaluated in terms of local control as the primary endpoint. Survival outcomes were also analysed to identify predictive factors for clinical outcomes. Toxicity was assessed according to CTCAE v4.0. RESULTS Between March 2018 and July 2022, 183 lesions in 177 patients were analysed. In most patients, SBRT was delivered to a single spine metastasis (82%) for a median total dose of 21 Gy (14-35 Gy) in three fractions (one to five fractions) and a median BED10 = 119 Gy (57.7-152 Gy). Local control rates were 90.3% at 1 year, 84.3% at 2 years and 84.3% at 3 years. Distant progression-free survival rates were 33.1%, 18.5% and 12.4% at 1, 2 and 3 years, with prostate histology (P = 0.023), oligorecurrent disease (P = 0.04) and BED10 > 100 Gy (P = 0.04) found to be predictive on univariate analysis. A further oligometastatic progression was observed in 33 patients (18.6%) treated with a second course of SBRT, reporting at univariate analysis improved overall survival rates (P = 0.01). Polymetastases-free survival rates were 57.8%, 43.4% and 32.4%; concurrent therapy was related to improved outcomes at multivariate analysis (P = 0.009). Overall survival rates were 91.8%, 79.6% and 65.9%, with prostate histology and non-cervical metastases related to better overall survival at multivariate analysis. Pain-flare after SBRT was recorded in 3.3%; five patients underwent surgical decompression after SBRT; there were no grade ≥3 adverse events. CONCLUSIONS In our experience of only oligometastatic patients, spine SBRT gave excellent results in terms of safety and efficacy. Prostate histology and oligorecurrent disease were predictive factors for improved clinical outcomes; also, patients who experienced a further oligoprogression after SBRT maintained a survival advantage compared with polymetastatic progression. No severe adverse events were reported.
Collapse
Affiliation(s)
- F Cuccia
- Radiotherapy Unit, ARNAS Civico Hospital, Palermo, Italy.
| | - E Pastorello
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), Italy
| | - C Franzese
- IRCCS Humanitas Research Hospital, Radiotherapy and Radiosurgery Department, Milan, Italy
| | - L Belgioia
- Radiation Oncology Department, San Martino Teaching Hospital, Genova University (DISSAL), Genoa, Italy
| | - M Bignardi
- Radiation Oncology Center, Fondazione Poliambulanza, Brescia, Italy
| | - M Federico
- Radiation Therapy Unit, Clinica Macchiarella, Palermo, Italy
| | - V Figlia
- Radiotherapy Unit, ARNAS Civico Hospital, Palermo, Italy
| | - N Giaj Levra
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), Italy
| | - S Badellino
- Department of Oncology, University of Turin, Turin, Italy
| | - P Borghetti
- Radiation Oncology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy
| | - G Marvaso
- Division of Radiation Oncology, IEO European Institute of Oncology IRCCS, Milan, Italy
| | - G Montesi
- Radiation Oncology Unit, Santa Maria Della Misericordia Hospital, Rovigo, Italy
| | - A Pontoriero
- Radiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy
| | - I Fazio
- Radiation Therapy Unit, Clinica Macchiarella, Palermo, Italy
| | - G Ferrera
- Radiotherapy Unit, ARNAS Civico Hospital, Palermo, Italy
| | - F Alongi
- Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella (VR), Italy; University of Brescia, Brescia, Italy
| | - M Scorsetti
- IRCCS Humanitas Research Hospital, Radiotherapy and Radiosurgery Department, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy
| |
Collapse
|
4
|
Chiattone C, Miranda E, Gonzaga Y, Dias M, Salvino MA, Baptista RLR, Bortucchi D, Christofoletti T, Duffles G, Bellesso M, Pereira J, Brasil SAB, Castro NS, Cecyn KZ, Schaffel R, Tavares JV, Figueiredo VLP, Nogueira FL, Silva NAHL, Silva GF, Cunha-Junior AD, Gaiolla R, Duarte FB, Souza RR, Hallack-Neto A, Cordeiro A, Rabelo YS, Delamain MT, Federico M, Souza CA. A PREVENÇÃO DEVE SER A MELHOR ESTRATÉGIA PARA ENFRENTAR A LEUCEMIA/LINFOMA DE CÉLULAS-T DE ADULTO DO PROJETO T-CELL BRASIL. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
5
|
Chiattone CS, Miranda E, Pereira J, Cecyn KZ, Castro NS, Brasil SAB, Farias DFC, Bellesso M, Duffles G, Borducchi D, Gonzaga Y, Baptista RLR, Vilarim CC, Macedo CCG, Dias M, Salvino MA, Tavares JV, Nabhan S, Cunha-Junior AD, Zing N, Silva GF, Ribeiro GN, Negreiros E, Schaffel R, Figueiredo VLP, Souto-Filho JTD, Radtke PPG, Pont MD, Nogueira FL, Hamerschlak N, Cle DV, Gaiolla R, Duarte FB, Souza RR, Mo S, Hallack-Neto A, Rabelo YS, Ribeiro EFO, Cordeiro A, Perini G, Bueno ND, Matedi MAL, Cury P, Delamain MT, Federico M, Souza CA. PROJETO T-CELL BRASIL: ATUALIZAÇÃO DO PROJETO PIONEIRO DE COLETA DE DADOS DE PACIENTES COM LNH DE CÉLULAS T NAS CINCO REGIÕES BRASILEIRAS. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
|
6
|
Lage LAPC, Machado PPF, Reichert CO, Miranda E, Culler HF, Souza CA, Federico M, Rocha V, Pereira J, Chiattone CS. CLINICAL OUTCOMES, PROGNOSTIC FACTORS AND THERAPEUTIC MANAGEMENT IN EXTRANODAL NATURAL-KILLER/T-CELL LYMPHOMA, NASAL-TYPE (ENKTL-NT) – RESULTS OF THE MULTICENTER T-CELL BRAZIL PROJECT. Hematol Transfus Cell Ther 2022. [DOI: 10.1016/j.htct.2022.09.165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
7
|
Chiattone CS, Delamain MT, Miranda ECM, Pereira J, Farias DLC, Nabhan S, Bellesso M, Hamerschlak N, Zing N, Castro N, Ribeiro G, Baptista RLR, Gonzaga Y, Gaiolla R, Cordeiro A, Schaffel R, Souto-Filho JTD, Negreiros E, Hallack-Neto A, Ribeiro EFO, Vilarim CC, Macedo CCG, Brasil SAB, Mo SKG, Cunha-Junior AD, Cury P, Cecyn KZ, Duffles G, Federico M, Souza CA. O PAPEL DO TRANSPLANTE NOS LINFOMAS DE CÉLULAS T: DADOS PRELIMINARES DO PROJETO T-CELL BRASIL. Hematol Transfus Cell Ther 2021. [DOI: 10.1016/j.htct.2021.10.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Skrypets T, Stepanishyna Y, Galli GR, Manni M, Hubareva A, Tytorenko I, Martynchyk A, Aleksik O, Shudrak N, Pastushenko Y, Novosad O, Filonenko K, Kadnikova T, Kushchevyi Y, Federico M, Kriachok I. SUBTYPES OF MALIGNANT LYMPHOMAS IN UKRAINE, ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE UKRAINIAN LYMPHOMA REGISTRY. Hematol Oncol 2021. [DOI: 10.1002/hon.108_2881] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- T. Skrypets
- University of Modena and Reggio Emilia PhD Program in Clinical and Experimental Medicine Modena Italy
| | - Y. Stepanishyna
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - G. R. Galli
- Associazione Angela Serra Associazione Angela Serra for Cancer Research Lecce Italy
| | - M. Manni
- University of Modena and Reggio Emilia CHIMOMO Modena Italy
| | - A. Hubareva
- Ukrainian Lymphoma Study Group Ukrainian Lymphoma Study Group Kyiv Ukraine
| | - I. Tytorenko
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - A. Martynchyk
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - O. Aleksik
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - N. Shudrak
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - Y. Pastushenko
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - O. Novosad
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - K. Filonenko
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - T. Kadnikova
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - Y. Kushchevyi
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| | - M. Federico
- University of Modena and Reggio Emilia CHIMOMO Modena Italy
| | - I. Kriachok
- National Cancer Institute Department of Oncohematology Kyiv Ukraine
| |
Collapse
|
9
|
Aurer I, Neven A, Fiaccadori V, Counsell N, Phillips E, Clifton‐Hadley L, Fortpied C, Andre M, Federico M, Barrington S, Illidge T, Radford J, Raemaekers J. RELAPSES IN INTERIM PET NEGATIVE LIMITED STAGE HODGKIN LYMPHOMA PATIENTS RECEIVING ABVD WITH OR WITHOUT RADIOTHERAPY–ANALYSIS OF EORTC/FIL/LYSA H10 AND UK NCRI RAPID TRIALS. Hematol Oncol 2021. [DOI: 10.1002/hon.71_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- I. Aurer
- University Hospital Centre Zagreb Division of Hematology Department of Internal Medicine Zagreb Croatia
| | - A. Neven
- European Organisation for Research and Treatment of Cancer Lymphoma Group Brussels Belgium
| | - V. Fiaccadori
- University College London Cancer Institute London UK
| | - N. Counsell
- University College London Cancer Research UK and University College London Cancer Trials Centre London UK
| | - E. Phillips
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - L. Clifton‐Hadley
- University College London Cancer Research UK and University College London Cancer Trials Centre London UK
| | - C. Fortpied
- European Organisation for Research and Treatment of Cancer Lymphoma Group Brussels Belgium
| | - M. Andre
- Université Catholique de Louvain Department of Hematology Yvoir Belgium
| | - M. Federico
- University of Modena and Reggio Emilia CHIMOMO Department Modena Italy
| | - S. Barrington
- King's College London King's College London and Guy's and St Thomas' PET Centre London UK
| | - T. Illidge
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - J. Radford
- University of Manchester The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - J. Raemaekers
- Radboud University Medical Centre Department of Hematology Nijmegen Netherlands
| |
Collapse
|
10
|
Luminari S, Galimberti S, Versari A, Tucci A, Boccomini C, Farina L, Zaja F, Marcheselli L, Ferrero S, Arcaini L, Pulsoni A, Musuraca G, Califano C, Merli M, Bari A, Conconi A, Giudice ID, Re F, Stefani PM, Usai SV, Perrone T, Gini G, Falini B, Gattei V, Manni M, Ladetto M, Mannina D, Federico M. RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.80_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S. Luminari
- Azienda Unità Sanitaria Locale IRCCS Arcispedale Santa Maria Nuova IRCCS Hematology Unit and University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Reggio Emilia Italy
| | - S. Galimberti
- University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - A. Versari
- Azienda Unità Sanitaria Locale‐IRCCS ‐ Arcispedale Santa Maria Nuova Medicina Nucleare Reggio Emilia Italy
| | - A. Tucci
- ASST Spedali Civili di Brescia SC Ematologia Brescia Italy
| | - C. Boccomini
- A.O.U. Città della Salute e della Scienza di Torino SC Ematologia Torino Italy
| | - L. Farina
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology Milano Italy
| | - F. Zaja
- Università degli Studi di Trieste Dipartimento Clinico di Scienze mediche, chirurgiche e della salute and, Azienda Sanitaria Universitaria Giuliano Isontina SC Ematologia Trieste Italy
| | | | - S. Ferrero
- University of Torino, Hematology Department of Molecular Biotechnologies and Health Sciences and AOU “Città della Salute e della Scienza di Torino” Hematology 1 Torino Italy
| | - L. Arcaini
- Fondazione IRCCS Policlinico San Matteo di Pavia Division of Hematology and University of Pavia Department of Molecular Medicine Pavia Italy
| | - A. Pulsoni
- Sapienza Università di Roma Dipartimento di Biotecnologie Cellulari ed Ematologia Roma Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Department of Hematology Meldola Italy
| | - C. Califano
- Ospedale Umberto I, U.O Medicina‐Oncoematologia Nocera Inferiore Italy
| | - M. Merli
- University Hospital Ospedale di Circolo e Fondazione Macchi ASST Settelaghi Varese Italy
| | - A. Bari
- Università di Modena e Reggio Emilia Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Modena Italy
| | - A. Conconi
- Ospedale degli Infermi Unit of Hematology Biella Italy
| | - I. del Giudice
- Policlinico Umberto I ‐ Università "La Sapienza" ‐ Istituto Ematologia Dipartimento di Medicina Traslazionale e di Precisione Roma Italy
| | - F. Re
- Azienda Ospedaliero Universitaria di Parma UO Ematologia e CTMO Parma Italy
| | - P. M. Stefani
- General Hospital Ca' Foncello Hematology Treviso Italy
| | - S. V. Usai
- Ospedale Oncologico Armando Businco Division of Hematology Cagliari Italy
| | - T. Perrone
- University of Bari Hematology Bari Italy
| | - G. Gini
- Marche Polytechnic University Department of Clinical and Molecular Sciences, Hematology Ancona Italy
| | - B. Falini
- Ospedale S. Maria della Misericordia University of Perugia Institute of Hematology and CREO (Center for Hemato‐Oncological Research) Perugia Italy
| | - V. Gattei
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Clinical and Experimental Onco‐Hematology Unit Aviano Italy
| | - M. Manni
- University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Modena Italy
| | - M. Ladetto
- Università del Piemonte Orientale Dipartimento di Medicina Traslazionale and AO SS Antonio e Biagio e Cesare Arrigo SC Ematologia Alessandria Italy
| | - D. Mannina
- Azienda Ospedaliera Papardo UOC di Ematologia Messina Italy
| | - M. Federico
- University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine Modena Italy
| |
Collapse
|
11
|
Phillips EH, Counsell N, Illidge T, Andre M, Aurer I, Fiaccadori V, Fortpied C, Neven A, Federico M, Clifton‐Hadley L, Barrington S, Raemaekers J, Radford J. BASELINE MAXIMUM TUMOUR DIAMETER IS ASSOCIATED WITH EVENT‐FREE SURVIVAL FOR PET‐NEGATIVE PATIENTS WITH LIMITED‐STAGE HODGKIN LYMPHOMA: ANALYSIS OF THE H10 AND RAPID TRIALS. Hematol Oncol 2021. [DOI: 10.1002/hon.115_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- E. H. Phillips
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - N. Counsell
- University College London, Cancer Research UK and UCL Cancer Trials Centre London UK
| | - T. Illidge
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| | - M. Andre
- CHU UCL Namur, Department of Haematology Yvoir Belgium
| | - I. Aurer
- University Hospital Centre Zagreb, Division of Hematology, Department of Internal Medicine Zagreb Croatia
| | - V. Fiaccadori
- University College London, Cancer Institute London UK
| | - C. Fortpied
- European Organisation for Research and Treatment of Cancer, EORTC Headquarters Brussels Belgium
| | - A. Neven
- European Organisation for Research and Treatment of Cancer, EORTC Headquarters Brussels Belgium
| | - M. Federico
- University of Modena and Reggio Emilia, CHIMOMO Department Modena Italy
| | - L. Clifton‐Hadley
- University College London, Cancer Research UK and UCL Cancer Trials Centre London UK
| | - S. Barrington
- King's College London and King's Health Partners, King's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences London UK
| | - J. Raemaekers
- Radboud University Medical Center, Department of Haematology Nijmegen Netherlands
| | - J. Radford
- University of Manchester, The Christie NHS Foundation Trust and NIHR Manchester Biomedical Research Centre Manchester UK
| |
Collapse
|
12
|
Federico M, Chiattone CS, Prince HM, Pavlovsky A, Manni M, Civallero M, Skrypets T, De Souza CA, Hawkes EA, Fiad L, Lymboussakis A, Tomuleasa C, Nair R, Pereira J, Pereyra P, Minoia C, Kryachok I, de Castro NS, Advani RH, Luminari S. SUBTYPES OF MATURE T AND NK CELL LYMPHOMAS ACCORDING TO 2016 WHO CLASSIFICATION. PRELIMINARY REPORT OF THE INTERNATIONAL PROSPECTIVE T‐CELL PROJECT 2.0. Hematol Oncol 2021. [DOI: 10.1002/hon.135_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- M Federico
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C. S Chiattone
- Santa Casa de Sao Paulo School of Medical Sciences São Paulo Brazil
| | - H. M Prince
- Epworth Healthcare, East Melbourne Richmond Australia
| | - A Pavlovsky
- Fundaleu, Haematology Buenos Aires Argentina
| | - M Manni
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - M Civallero
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - T Skrypets
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | | | - E. A Hawkes
- Lymphoma and Related Diseases Registry School of Public Health and Preventive Medicine Monash University and Olivia Newton John Cancer Research Institute Austin Health, Melbourne Australia
| | - L Fiad
- Hospital Italiano La Plata Department of Hematology and Oncology Buenos Aires Argentina
| | - A Lymboussakis
- University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - C Tomuleasa
- Ion Chiricuta Oncology Institute Department of Hematology Cluj Napoca Romania
| | - R Nair
- TATA Medical Center, Clinical Haematology Oncology Kolkata India
| | - J Pereira
- Universidade de São Paulo Hospital das Clínicas da Faculdade de Medicina São Paulo Brazil
| | - P Pereyra
- Hospital Nacional Dr. Prof. Alejandro Posadas Hematology Buenos Aires Argentina
| | - C Minoia
- IRCCS Cancer Institute "Giovanni Paolo II" Haematology Unit Bari Italy
| | - I Kryachok
- National Cancer Institute Oncohematology Department Kiev Ukraine
| | - N. S de Castro
- Hospital de Cancer de Barretos, Hematology, Barretos São Paulo Brazil
| | - R. H Advani
- Stanford Cancer Center Blood and Marrow Transplant Program, Stanford California USA
| | - S Luminari
- Azienda Unità Sanitaria Locale IRCCS, Arcispedale Santa Maria Nuova IRCCS, Hematology Unit and University of Modena and Reggio Emilia, Surgical Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Reggio Emilia Italy
| |
Collapse
|
13
|
Conconi A, Vannata B, Janikova A, Ramirez A, Bodoni CL, Nowakowski G, Mian M, Ferreri AJ, Ryan G, Pangalis GA, Cabrera ME, Luminari S, Montoto S, Tsang R, Aurer I, Visco C, Mazzucchelli L, Trneny M, Gaidano G, Federico M, Lopez‐Guillermo A, Pro B, Zucca E. PRIMARY EXTRANODAL FOLLICULAR LYMPHOMA IN A LARGE RETROSPECTIVE SURVEY OF THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG31). Hematol Oncol 2021. [DOI: 10.1002/hon.78_2879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Conconi
- Azienda sanitaria locale Biella Ospedale degli Infermi ‐ Ematologia Biella Italy
| | - B. Vannata
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - A. Janikova
- University Hospital Brno Department of Hematology and Oncology Brno Czech Republic
| | - A. Ramirez
- Instituto Nacional de Cancerologia Hematology Department Mexico City Mexico
| | - C. Lobetti Bodoni
- Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| | - G. Nowakowski
- Mayo Clinic Division of Hematology Rochester Minnesota USA
| | - M. Mian
- Ospedale di Bolzano Ematologia e Centro Trapianto Midollo Osseo Bolzano Italy
| | - Andrés J.M. Ferreri
- IRCCS San Raffaele Scientific Institute Unità Operativa di Oncologia Medica Milano Italy
| | - G. Ryan
- Peter MacCallum Cancer Institute Deptment of Radiation Oncology Melbourne Australia
| | - G. A. Pangalis
- Athens Medical Center‐Psychikon Branch Hematology Department Athens Greece
| | - M. E. Cabrera
- Hospital del Salvador Facultad de Medicina Santiago Chile
| | - S. Luminari
- Arcispedale Santa Maria Nuova Servizio di Ematologia Reggio Emilia Italy
| | - S. Montoto
- St. Bartholomew’s Hospital Department of Medical Oncology London UK
| | - R. Tsang
- University Health Network Princess Margaret Hospital Toronto Canada
| | - I. Aurer
- University Hospital Centre Zagreb Division of Hematology Zagreb Croatia
| | - C. Visco
- University of Verona Departmento of Medicine ‐ Section of Hematology Verona Italy
| | | | - M. Trneny
- Charles University General Hospital Prague First Faculty of Medicine Prague Czech Republic
| | - G. Gaidano
- Azienda Ospedaliera "Maggiore della Carità" Ematologia Novara Italy
| | - M. Federico
- Università degli Studi di Modena e Reggio Emilia Centro Oncologico Modenese Modena Italy
| | | | - B. Pro
- Northwestern Medicine Hematology and Medical Oncology Chicago Illinois USA
| | - E. Zucca
- Foundation for the Institute of Oncology Research (IOR) International Extranodal Lymphoma Study Group Oncology Institute of Southern Switzerland Medical Oncology Clinic Bellinzona Switzerland
| |
Collapse
|
14
|
Luminari S, Guerra L, Durmo R, Chauvie S, Peano S, Franceschetto A, Fallanca F, Tarantino V, Pinto A, Ghiggi C, Pulsoni A, Merli M, Farina L, Tani M, Botto B, Musuraca G, Falini B, Ballerini F, Stefani PM, Bolis S, Pietrantuono G, Manni M, Marcheselli L, Federico M, Versari A. EARLY METABOLIC RESPONSE IN FOLLICULAR LYMPHOMA: A SUBSET ANALYSIS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL). Hematol Oncol 2021. [DOI: 10.1002/hon.33_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S. Luminari
- Azienda Unità Sanitaria Locale IRCCS Arcispedale Santa Maria Nuova IRCCS, Hematology Unit and University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Reggio Emilia Italy
| | - L. Guerra
- S. Gerardo Hospital University of Milano‐Bicocca, Nuclear Medicine and , University of Milano Bicocca School of Medicine and Surgery Monza Italy
| | - R. Durmo
- Azienda USL‐IRCCS di Reggio Emilia Nuclear Medicine Reggio Emilia Italy
| | - S. Chauvie
- Santa Croce e Carle Hospital Department of Medical Physics Cuneo Italy
| | - S. Peano
- ASO S. Croce e Carle S.C. Medicina Nucleare Cuneo Italy
| | - A. Franceschetto
- Modena Cancer Center University of Modena and Reggio Emilia Department of Oncology and Hematology Unit of Nuclear Medicine Modena Italy
| | - F. Fallanca
- IRCCS San Raffaele Scientific Institute Nuclear Medicine Unit Milano Italy
| | - V. Tarantino
- University of Modena and Reggio Emilia PhD program in Clinical and Experimental Medicine (CEM) Modena Italy
| | - A. Pinto
- National Cancer Institute Fondazione "G. Pascale" IRCCS Hematology‐Oncology and Stem Cell Transplantation Unit Napoli Italy
| | - C. Ghiggi
- IRCCS San Martino Hospital Hematology and Transplant Center Division Genoa Italy
| | - A. Pulsoni
- Sapienza Università di Roma Dipartimento di Biotecnologie Cellulari ed Ematologia Roma Italy
| | - M. Merli
- University Hospital Ospedale di Circolo e Fondazione Macchi ASST Settelaghi Varese Italy
| | - L. Farina
- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Division of Hematology Milano Italy
| | - M. Tani
- Ospedale Civile S Maria delle Croci Azienda Unità Sanitaria Locale (AUSL) Ravenna Italy
| | - B. Botto
- A.O.U. Città della Salute e della Scienza di Torino SC Ematologia Torino Italy
| | - G. Musuraca
- IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" Department of Hematology Meldola Italy
| | - B. Falini
- University of Perugia, Institute of Hematology and CREO (Center for Hemato‐Oncological Research) Ospedale S. Maria della Misericordia Perugia Italy
| | - F. Ballerini
- IRCCS Ospedale Policlinico San Martino University of Genoa Clinica Ematologica Genova Italy
| | - P. M. Stefani
- General Hospital Ca' Foncello Hematology Treviso Italy
| | - S. Bolis
- ASST MONZA, SC di Ematologia Monza Italy
| | - G. Pietrantuono
- IRCCS Centro di Riferimento Oncologico della Basilicata Hematology and Stem Cell Transplantation Unit Rionero in Vulture Italy
| | - M. Manni
- University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | | | - M. Federico
- University of Modena and Reggio Emilia Surgical, Medical and Dental Department of Morphological Sciences related to Transplant Oncology and Regenerative Medicine Modena Italy
| | - A. Versari
- Azienda USL‐IRCCS di Reggio Emilia Nuclear Medicine Reggio Emilia Italy
| |
Collapse
|
15
|
Federico M, Rey-Baltar Oramas M, Tornero A. OC-0063 Peritoneal spacing reduce OAR dose in cervical cancer BT. Preliminary results of a pilot study. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06296-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
16
|
Nogueira D, Delamain M, Miranda E, Gonzaga Y, Pereira J, Lyrio R, Bellesso M, Brasil S, Dias M, Schaffel R, Rabelo Y, Jr A, Carneiro T, Neto A, Castro N, Gaiolla R, Mo S, Silveira T, Federico M, Vassalo J, Souza C, Chiattone C. CARACTERÍSTICAS CLÍNICAS E DESFECHOS DA LEUCEMIA/LINFOMA DE CÉLULAS T DO ADULTO NO BRASIL: UM ESTUDO OBSERVACIONAL. Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.10.360] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
17
|
Chiattone C, Delamain M, Miranda E, Castro N, Brasil S, Bellesso M, Pereira J, Cunha-Junior A, Gonzaga Y, Nabhan S, Ribeiro G, Lyrio R, Zing N, Carneiro T, Berg A, Nogueira D, Schaffel R, Cecyn K, Souto-Filho J, Hamerschlak N, Gaiolla R, Dias M, Pont M, Hallack-Neto A, Rabelo Y, Duarte F, Sousa R, Mo S, Silveira T, Cury P, Vassallo J, Federico M, Souza C. ATUALIZAÇÃO DO ESTUDO AMBISPECTIVO DO REGISTRO DE LINFOMA DE CÉLULAS-T, NAS CINCO MACRORREGIÕES BRASILEIRAS. Hematol Transfus Cell Ther 2020. [DOI: 10.1016/j.htct.2020.10.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
18
|
Gac A, Chartier L, Girinsky T, Gotti M, Lazarovici J, Aurer I, Musto P, Damaj G, Federico M, Fortpied C, Raemaekers J, Meignan M, Hutchings M, Versati A, Andre M, Reman O. OUTCOME AND TREATMENT OF RELAPSING EARLY PET NEGATIVE PATIENTS INCLUDED IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.104_2630] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Gac
- Institut d'Hématologie de Basse-Normandie; Centre Hospitalier Universitaire; Caen France
| | - L. Chartier
- Pôle Biométrie-Biostatistiques; LYSARC; Pierre Bénite France
| | - T. Girinsky
- Département de Radiothérapie; Institut de Cancérologie Gustave Roussy; Villejuif France
| | - M. Gotti
- Department of Hematology Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - J. Lazarovici
- Département d'Hématologie; Institut de Cancérologie Gustave Roussy; Villejuif France
| | - I. Aurer
- Zavod za Hematologiju; Klinike i Zavodi za Unutarnje Bolesti; Zagreb Croatia
| | - P. Musto
- Referral Cancer Center of Basilicata; IRCCS-CROB; Rionero in Vulture (Pz) Italy
| | - G. Damaj
- Département d'hématologie; université de Basse-Normandie; Caen France
| | - M. Federico
- University of Modena and Reggio Emilia; Department of Diagnostic, Clinical and Public Health Medicine; Modena Italy
| | - C. Fortpied
- Department of Statistic; EORTC; Brussels Belgium
| | - J. Raemaekers
- Department of Hematology; Radboud University Medical Center; Nijmegen Netherlands
| | - M. Meignan
- Département de Médecine Nucléaire; Hospital Henri Mondor; Creteil France
| | - M. Hutchings
- Department of Hematology; University Hospital Rigshospitalet; Copenhagen Denmark
| | - A. Versati
- Department of Nuclear Medicine; Arcispedale S. Maria Nuova; Reggio Emilia Italy
| | - M. Andre
- Département d'Hématologie; Université Catholique de Louvain; YVOIR Belgium
| | - O. Reman
- Institut d'Hématologie de Basse-Normandie; Centre Hospitalier Universitaire; Caen France
| |
Collapse
|
19
|
Lopez-Parra M, Bellei M, Rambaldi A, Novelli S, Panizo C, Martelli M, Dhouly I, Bastos M, Gutierrez A, Sancho J, Ramirez M, Moraleda J, Carrillo Cruz E, Jimenez Ubieto A, Jarque I, Vittolo U, de las Heras N, Arranz R, Lopez-Jimenez J, Montalbán C, Pascual M, Corradini P, Bobillo S, Estefania G, Spina M, Rossi G, Manni M, Federico M, Caballero D, Martín A. AUTOLOGOUS STEM CELL TRANSPLANTATION AS PART OF FIRST-LINE THERAPY IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER GELTAMO/FIL STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.63_2629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- M. Lopez-Parra
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| | - M. Bellei
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena; Modena Italy
| | - A. Rambaldi
- Hematology and bone marrow transplant Unit; University of Milan; Milan Italy
| | - S. Novelli
- Hematology; Hospital de la Santa Creu i Sant Pau; Barcelona Spain
| | - C. Panizo
- Hematology; Clínica Universidad de Navarra; Pamplona Spain
| | - M. Martelli
- Hematology; Sapienza, University of Rome; Rome Italy
| | - I. Dhouly
- Hematology; Hospital Clinic de Barcelona; Barcelona Spain
| | - M. Bastos
- Hematology; Hospital Gregorio Marañón; Madrid Spain
| | - A. Gutierrez
- Hematology; Hospital Son de Espases; Palma Spain
| | - J. Sancho
- Hematology; Hospital Germans Trias i Pujol/ ICO-IJC; Barcelona Spain
| | - M. Ramirez
- Hematology; Hospital de Jerez de la Frontera; Jerez de la Frontera Spain
| | - J. Moraleda
- Hematology; Hospital Vírgen de la Arrixaca; Murcia Spain
| | | | | | - I. Jarque
- Hematology; Hospital Universitario y Politécnico La Fe; Valencia Spain
| | - U. Vittolo
- Dipartimento di Oncologia e Ematologia; Città della Salute e della Scienza di Torino; Turin Italy
| | - N. de las Heras
- Hematology; Complejo Asistencial Universitario de León; León Spain
| | - R. Arranz
- Hematology; Hospital La Princesa; Madrid Spain
| | | | - C. Montalbán
- Hematology; MD Anderson Cancer Center; Madrid Spain
| | - M. Pascual
- Hematology; Hospital Carlos Haya; Málaga Spain
| | | | - S. Bobillo
- Hematology; University Hospital Vall d'Hebron; Barcelona Spain
| | | | - M. Spina
- Division of Medical Oncology; National Cancer Institute; Aviano Italy
| | - G. Rossi
- Hematology; Spedali Civili; Brescia Italy
| | - M. Manni
- Diagnostic; Clinic and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Hematology; Università degli Studi di Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| | - A. Martín
- Hematology; University Hospital of Salamanca-IBSAL; Salamanca Spain
| |
Collapse
|
20
|
Federico M, Mannina D, Versari A, Ferrero S, Marcheselli L, Boccomini C, Dondi A, Tucci A, Guerra L, Galimberti S, Cavallo F, Olivieri J, Corradini P, Arcaini L, Chauvie S, Del Giudice I, Rusconi C, Pinto A, Molinari A, Pulsoni A, Merli M, Kovalchuk S, Nassi L, Bolis S, Gattei V, Manni M, Pileri S, Brugiatelli M, Luminari S. RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2019. [DOI: 10.1002/hon.110_2629] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- M. Federico
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - D. Mannina
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - A. Versari
- Nuclear Medicine Unit; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - S. Ferrero
- Department of Molecular Biotechnologies and Health Sciences, Division of Hematology; University of Torino; Torino Italy
| | - L. Marcheselli
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - C. Boccomini
- SC Ematologia; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Dondi
- Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto; Fondazione Italiana Linfomi; Modena Italy
| | - A. Tucci
- SC Ematologia; ASST-Spedali Civili; Brescia Italy
| | - L. Guerra
- Nuclear Medicine Unit; San Gerardo Hospital; Monza Italy
| | - S. Galimberti
- Division of Hematology, Department of Oncology; Santa Chiara Hospital; Pisa Italy
| | - F. Cavallo
- Division of Hematology; University of Torino, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - J. Olivieri
- Clinica Ematologica; Centro Trapianti e Terapie Cellulari “C. Melzi”, DAME, ASUI; Udine Italy
| | - P. Corradini
- Department of Oncology and Hematology; Fondazione Istituto Nazionale dei Tumori Milano University of Milano; Milano Italy
| | - L. Arcaini
- Department of Molecular Medicine; University of Pavia, Division of Hematology, Fondazione IRCCS Policlinico S. Matteo; Pavia Italy
| | - S. Chauvie
- Medical Physics Unit; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - I. Del Giudice
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - C. Rusconi
- Division of Hematology; ASST Grande ospedale Metropolitano Niguarda; Milano Italy
| | - A. Pinto
- Department of Hematology and Developmental Therapeutics; Istituto Nazionale Tumori, Fondazione ‘G. Pascale’ IRCCS; Napoli Italy
| | - A. Molinari
- UO Ematologia; OC Rimini AUSL Romagna; Rimini Italy
| | - A. Pulsoni
- Hematology Unit, Department of Translational and Precision Medicine; Sapienza University of Rome; Roma Italy
| | - M. Merli
- Hematology; University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria; Varese Italy
| | - S. Kovalchuk
- Ematologia; Università degli Studi di Firenze; Firenze Italy
| | - L. Nassi
- Hematology; AOU Maggiore della Carità; Novara Italy
| | - S. Bolis
- Hematolgy Unit; ASST-Monza; Monza Italy
| | - V. Gattei
- Clinical and Experimental Onco-Haematology Unit; Centro di Riferimento Oncologico, IRCCS; Aviano Italy
| | - M. Manni
- Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche; University of Modena and Reggio Emilia; Modena Italy
| | - S. Pileri
- Divisione di Diagnosi Ematopatologica; Istituto Europeo di Oncologia; Milano Italy
| | - M. Brugiatelli
- UOC di Ematologia; Azienda Ospedaliera Papardo; Messina Italy
| | - S. Luminari
- S.C. Ematologia; Arcispedale S. Maria Nuova-IRCCS; Reggio Emilia Italy
| |
Collapse
|
21
|
Affiliation(s)
- M. Federico
- Medical Oncology, CHIMOMO Department; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- CHIMOMO Department; University of Modena and Reggio Emilia; Modena Italy
| | - M. Civallero
- CHIMOMO Department; University of Modena and Reggio Emilia; Modena Italy
| | - T. Skrypets
- CHIMOMO Department; University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
22
|
Batlevi C, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Hamlin P, Horwitz S, Kumar A, Matasar M, Moskowitz A, Moskowitz C, Noy A, Palomba M, Portlock C, Straus D, Boccomini C, Tucci A, Zelenetz A, Seshan V, Luminari S, Marcheselli L, Federico M, Younes A. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.109_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C.L. Batlevi
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - F. Sha
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Alperovich
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Ni
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - K. Smith
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - Z. Ying
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - P. Hamlin
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - S.M. Horwitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A. Kumar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M. Matasar
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - A.J. Moskowitz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C.H. Moskowitz
- Department of Medicine; University of Miami, Sylvester Cancer Center; Miami United States
| | - A. Noy
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - M.L. Palomba
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Portlock
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - D. Straus
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - C. Boccomini
- ASO Città della Salute e della Scienza di Torino; Ematologia; Turin Italy
| | - A. Tucci
- Department of Hematology; Spedali Civili di Brescia; Brescia Italy
| | - A.D. Zelenetz
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| | - V.E. Seshan
- Department of Epidemiology and Biostatistics; Memorial Sloan Kettering Cancer Center; New York United States
| | - S. Luminari
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - L. Marcheselli
- Department of Medical and Surgical Sciences, and FIL Trial Office; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine, Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Younes
- Department of Medicine; Lymphoma Service, Memorial Sloan Kettering Cancer Center; New York United States
| |
Collapse
|
23
|
Aleman B, Ricardi U, van der Maazen R, Meijnders P, Beijert M, Boros A, Izar F, Janus C, Levis M, Martin V, Specht L, Corning C, Clementel E, Fortpied C, Raemaekers J, Andre M, Federico M, Girinsky T. PRELIMINARY RESULTS OF A QUALITY CONTROL STUDY ON INVOLVED NODE RADIOTHERAPY IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.166_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- B.M. Aleman
- Radiation Oncology; The Netherlands Cancer Institute; Amsterdam Netherlands
| | - U. Ricardi
- Oncology; University of Turin; Turin Italy
| | | | - P. Meijnders
- Radiotherapy; GZA Ziekenhuizen campus Sint-Augustinus; Wilrijk Belgium
| | - M. Beijert
- Radiotherapy; University Medical Center Groningen; Groningen Netherlands
| | - A. Boros
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| | - F. Izar
- Radiotherapy; Institut universitaire du cancer de Toulouse; Toulouse France
| | - C.P. Janus
- Radiotherapy; Erasmus MC Cancer Institute; Rotterdam Netherlands
| | - M. Levis
- Oncology; University of Turin; Turin Italy
| | - V. Martin
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| | - L. Specht
- Oncology; Rigshospitalet; Copenhagen Denmark
| | - C. Corning
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - E. Clementel
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - C. Fortpied
- Head Quarters; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | | | - M.P. Andre
- Hematology; CHU UCL Mont-Godinne-Dinant; Yvoir Belgium
| | - M. Federico
- Oncology; University of Modena and Reggio Emilia; Modena Italy
| | - T. Girinsky
- Radiotherapy; Institut Gustave Roussy; Villejuif France
| |
Collapse
|
24
|
Shustov A, Cabrera M, Bellei M, Civallero M, Ko Y, Manni M, Horwitz S, Antonio De Souza C, Radford J, Varela S, Prates M, Ferreri A, Chiattone C, Spina M, Vose J, Chiappella A, Laszlo D, Marino D, Stelitano C, Skrypets T, Federico M. ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE: ANALYSIS OF 235 CASES COLLECTED BY THE T-CELL PROJECT. Hematol Oncol 2019. [DOI: 10.1002/hon.93_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- A. Shustov
- Division of Hematology; University of Washington Medical Center; Seattle United States
| | - M. Cabrera
- Seccion Hematologia; Hospital del Salvador, Universidad de Chile; Santiago Chile
| | - M. Bellei
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Civallero
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - Y.H. Ko
- Department of Pathology; Sungkyunkwan University; Seoul Republic of Korea
| | - M. Manni
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - S.M. Horwitz
- Department of Medical Oncology; Memorial Sloan-Kettering Cancer Ctr; New York United States
| | - C. Antonio De Souza
- Centro de Hematologia e Hemoterapia; University of Campinas; Campinas Brazil
| | - J. Radford
- Manchester Academic Health Science Centre; University of Manchester and the Christie NHS Foundation Trust; Manchester United Kingdom
| | - S.B. Varela
- Hospital Vall D/Hebron; University Hospital Vall D/Hebron; Barcelona Spain
| | - M.V. Prates
- Gatla; Laboratorio Varifarma sa; Buenos Aires Argentina
| | - A. Ferreri
- Unit of Lymphoid Malignancies; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - C. Chiattone
- Hematology Division; Santa Casa Medical School; São Paulo Brazil
| | - M. Spina
- Centro Di Riferimento Oncologico; Aviano Italy
| | - J.M. Vose
- Division of Oncology & Hematology; University of Nebraska Medical Center; Omaha NE United States
| | - A. Chiappella
- Hematology Division; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - D. Laszlo
- Division of Haemato-Oncology; Istituto Europeo di Oncologia; Milan Italy
| | - D. Marino
- Department of Clinical and Experimental Oncology; Veneto Institute of Oncology IOV-IRCCS Padova; Padua Italy
| | - C. Stelitano
- Department of Haematology; Grande Ospedale Metropolitano Bianchi Melacrino Morelli; Reggio Calabria Italy
| | - T. Skrypets
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Diagnostic; Clinical, and Public Health Medicine, University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
25
|
Guerra L, Bergesio F, Versari A, Franceschetto A, Peano S, Fallanca F, Storto G, Luminari S, Rigacci L, Gallamini A, Federico M, Chauvie S. INTERIM ANALYSIS OF CENTRAL REVIEW OF END-OF-THERAPY PET IN FOLL12 TRIAL FOR FOLLICULAR LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.62_2631] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- L. Guerra
- Nuclear Medicine; San Gerardo Hospital - ASST Monza; Monza Italy
| | - F. Bergesio
- Medical Physics; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - A. Versari
- Nuclear Medicine; AUSL-IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - A. Franceschetto
- Nuclear Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - S. Peano
- Nuclear Medicine; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| | - F. Fallanca
- Nuclear Medicine; San Raffaele Scientific Institute; Milano Italy
| | - G. Storto
- Nuclear Medicine; IRCCS-CROB Referral Cancer Center of Basilicata; Rionero in Vulture Italy
| | - S. Luminari
- Department of Diagnostic Medicine; Clinical and Public Health, University of Modena and Reggio Emilia; Modena Italy
| | - L. Rigacci
- Haematology and Stem Cells Transplantation Unit; San Camillo Forlanini Hospital; Roma Italy
| | - A. Gallamini
- Research and Clinical Innovation; Antoine Lacassagne Cancer Center; Nice France
| | - M. Federico
- CHIMOMO; University of Modena and Reggio Emilia; Modena Italy
| | - S. Chauvie
- Medical Physics; Azienda Ospedaliera S. Croce e Carle; Cuneo Italy
| |
Collapse
|
26
|
Federico M. ENDO 2019 - 101st Annual Meeting and Exposition of the Endocrine Society. New Orleans, Louisiana, USA - March 23-26, 2019. DRUG FUTURE 2019. [DOI: 10.1358/dof.2019.44.5.2996485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
27
|
Eichenauer DA, Aleman BMP, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M. Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv19-iv29. [PMID: 29796651 DOI: 10.1093/annonc/mdy080] [Citation(s) in RCA: 193] [Impact Index Per Article: 32.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Affiliation(s)
- D A Eichenauer
- First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
| | - B M P Aleman
- Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M André
- Université Catholique de Louvain, Yvoir
- Department of Hematology, CHU UCL Namur, Yvoir, Belgium
| | - M Federico
- Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy
| | - M Hutchings
- Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - T Illidge
- Division of Cancer Sciences, University of Manchester, Manchester
- The Christie NHS Foundation Trust, Manchester, UK
| | - A Engert
- First Department of Internal Medicine, University Hospital Cologne, Cologne, Germany
| | - M Ladetto
- Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
| |
Collapse
|
28
|
Federico M, Sabbatini R, Piccinini P, Zironi S, Piccinini L, Silingardi V. Prevention of Cisplatin-Induced Vomiting in Patients with Cancer. A Pilot Study with a Multiagent Protocol. Tumori 2018; 76:278-81. [PMID: 2368173 DOI: 10.1177/030089169007600314] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Forty patients receiving a total of 102 courses of cisplatin (CDDP)-based treatment were observed in the present study. The patients received an antiemetic prophylaxis with metoclopramide (6 mg/kg), dexamethasone (12 mg/m2), lorazepam (2.5 mg), promethazine (50 mg), and diazepam (10 mg). Complete protection from acute vomiting was obtained in 77.5% of patients during the first course, and partial protection (1 to 3 episodes of vomiting) was observed in 10.1% additional cases. Complete protection was achieved in 84.6% of males vs 57.1% of females. Patients at their first course of chemotherapy had 80% complete protection compared to 66.7% In those who received prior chemotherapy. No differences in the response rate between patients treated with high versus patients receiving low doses of CDDP were noted. The same pattern of response was observed in subsequent courses of therapy. Side effects were minimal (mild sedation in almost all the cases and hiccups in a few cases). No major extrapyramidal reaction was observed. The regimen used in the study showed good efficacy in preventing acute CDDP-induced nausea and vomiting. Moreover, the very low incidence of major side effects makes this protocol safe and recommendable in patients undergoing CDDP chemotherapy.
Collapse
Affiliation(s)
- M Federico
- Department of Internal Medicine, University of Modena, Policlinico, Italy
| | | | | | | | | | | |
Collapse
|
29
|
Abstract
Current methods for the study of bone marrow to evaluate possible primary or metastatic cancers are reviewed. Bone marrow biopsy, radionuclide scan, computed tomography and magnetic resonance imaging (MRI) are analyzed with regard to their clinical usefulness at the time of diagnosis and during the course of the disease. Bone marrow biopsy is still the examination of choice not only in hematologic malignancies but also for tumors that metastasize into the marrow. Radionuclide scans are indicated for screening for skeletal metastases, except for those from thyroid carcinoma and multiple myeloma. Computed tomography is useful for cortical bone evaluation. MRI shows a high sensitivity in finding occult sites of disease in the marrow but its use has been restricted by high cost and limited availability. However, the future of MRI in bone marrow evaluation seems assured. MRI is already the method of choice for diagnosis of multiple myeloma, when radiography is negative, and for quantitative evaluation of lymphoma when a crucial therapeutic decision (i.e. bone marrow transplantation) must be made. Finally, methods are being developed that will enhance the sensitivity and specificity of MRI studies of bone marrow.
Collapse
Affiliation(s)
- M Federico
- Divisione di Oncologia, Università di Modena, Italy
| | | | | | | | | |
Collapse
|
30
|
Gatta G, Buiatti E, Conti E, De Lisi V, Falcini F, Federico M, Gafà L, Ponz de Leon M, Vercelli M, Zanetti R. Variations in the Survival of Adult Cancer Patients in Italy. Tumori 2018; 83:497-504. [PMID: 9152470 DOI: 10.1177/030089169708300112] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims As part of the ITACARE project, the present study analyzed and compared population-based data on the survival of adult cancer patients in Italy, according to sex, age, period of diagnosis and geographical area. Methods Nine Italian population-based cancer registries provided data on all their cancer patients (total 90,431 cases) followed for at least 5 years and diagnosed during the period 1978–1989. About 10% of the Italian population is covered by these registries. The data was analyzed by means of a multivariate model. Results The major findings were that there was a general improvement in 5-year relative survival over the study period (from 33% to 39%) and that there were significant differences in survival between different areas of the country, particularly for cancer sites which respond well to treatment. In general, the area covered by the Ragusa (Sicily) registry was characterized by significantly worse survival than other registry populations. Other important findings were that for all malignant cancer sites 5-year relative survival decreased with age from 50% for the youngest age class (15–44 years) to 27% for the oldest age class (75+ years) and that women have a better prognosis for most cancer sites (overall 5-year relative survival in women 48% vs 32% in men). Conclusions The significant regional differences in survival may reflect unequal provision of care, particularly between northern-central Italy and the south. The reasons for the general survival improvement with time are not completely understood, whereas the marked overall sex difference is related to the fact that the commonest cancer in women (breast cancer) is eminently more treatable than the commonest malignancy in men (lung cancer). The unfavorable trend with increasing age may be due to increasing difficulty in applying complete therapy protocols as general health declines, sometimes in relation to an advanced cancer stage at diagnosis.
Collapse
Affiliation(s)
- G Gatta
- Istituto Nazionale per la Cura e lo Studio dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Ordoñez Marmolejo R, Henriquez-Hernandez L, Pinar B, Federico M, Lloret M, Rodriguez Ibarria M, Ribeiro I, Garcia-Cabrera L, Rodríguez-Gallego C, Lara P. EP-2333: NK and B cells are novel prognostic factors for disease free survival in cervical carcinoma patients. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)32642-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
32
|
Rossi S, Crocetti E, Capocaccia R, Gatta G, Buzzoni C, Giacomin A, Zanetti R, Bisanti L, Tessandori R, Crosignani P, Vercelli M, Mazzoleni G, Piffer S, Zambon P, Serraino D, Ferretti S, Michiara M, Federico M, de Leon MP, Mangone L, Falcini F, Crocetti E, La Rosa F, Vitarelli S, Pannozzo F, Fusco M, Donato A, Traina A, Tumino R, Madeddu A, Contrino M, Budroni M. Estimates of cancer burden in Italy. Tumori 2018; 99:416-24. [DOI: 10.1177/030089161309900318] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and background This paper presents updated estimates of the incidence, prevalence and mortality of stomach, colorectal, lung, breast, uterine cervix and prostate cancer and skin melanoma in the Italian population. In particular, point estimates for 2012 and time trends from 1970 to 2015 will be provided. Methods The presented figures were obtained by summing up the regional epidemiological indicator estimates presented in the other papers of this monographic issue, which were derived by applying the MIAMOD statistical back-calculation method to cancer registries survival data and official mortality rates. Results Our findings indicate that breast, colon-rectum and prostate will be the cancer sites with the highest incidence rates in the forthcoming years. The incidence rates still tend to increase for breast, male colorectal cancer and female lung cancer as well as for skin melanoma. By contrast, the incidence of stomach cancer, cervical cancer and male lung cancer, by far the most common tumor sites up to the early 1990s, will continue to decrease. The mortality estimates showed a decreasing trend for all considered cancers with the only exception of lung cancer in women. Conclusion These results point to the need to reinforce prevention activities by developing more effective preventive measures for population groups at risk. There is also a need to support timely and continuous cancer surveillance in the Italian population through cancer registries in order to monitor the spread of the cancer risk and to evaluate the impact of prevention policies and therapeutic advances.
Collapse
Affiliation(s)
- Silvia Rossi
- National Center of Epidemiology, Italian National Institute of Health, Rome
| | - Emanuele Crocetti
- Tuscany Cancer Registry, Cancer Prevention and Research Institute (ISPO), Florence
- AIRTUM National Secretary
| | | | - Gemma Gatta
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | | | - R. Zanetti
- Registro tumori Piemonte, città di Torino
| | | | | | | | - M. Vercelli
- Registro tumori Liguria, Provincia di Genova, UOS Epidemiologia descrittiva, IRCSS AOU SMIST/UNIGE
| | - G. Mazzoleni
- Registro tumori dell'Alto Adige-Tumorregister SüdTirol
| | - S. Piffer
- Registro tumori della Provincia di Trento
| | | | | | | | | | | | | | | | | | - E. Crocetti
- AIRTUM National Secretary, Registro tumori Regione Toscana
| | | | | | | | - M. Fusco
- Registro tumori di popolazione Regione Campania
| | - A. Donato
- Registro tumori della Provincia di Salerno
| | - A. Traina
- Registro tumori della Mammella di Palermo
| | - R. Tumino
- Registro tumori della Provincia di Ragusa
| | | | | | - M. Budroni
- Registro tumori della Provincia di Sassari
| | | |
Collapse
|
33
|
Federico M, Cole P, Bofill X. United States and Canadian Academy of Pathology (USCAP) - 107th Annual Meeting. Vancouver, BC, Canada - March 17-23, 2018. DRUG FUTURE 2018. [DOI: 10.1358/dof.2018.043.05.2808557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
34
|
Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, Allemani C, Bouzbid S, Hamdi-Chérif M, Zaidi Z, Bah E, Swaminathan R, Nortje S, El Mistiri M, Bayo S, Malle B, Manraj S, Sewpaul-Sungkur R, Fabowale A, Ogunbiyi O, Bradshaw D, Somdyala N, Stefan D, Abdel-Rahman M, Jaidane L, Mokni M, Kumcher I, Moreno F, González M, Laura E, Espinola S, Calabrano G, Carballo Quintero B, Fita R, Garcilazo D, Giacciani P, Diumenjo M, Laspada W, Green M, Lanza M, Ibañez S, Lima C, Lobo de Oliveira E, Daniel C, Scandiuzzi C, De Souza P, Melo C, Del Pino K, Laporte C, Curado M, de Oliveira J, Veneziano C, Veneziano D, Latorre M, Tanaka L, Azevedo e Silva G, Galaz J, Moya J, Herrmann D, Vargas S, Herrera V, Uribe C, Bravo L, Arias-Ortiz N, Jurado D, Yépez M, Galán Y, Torres P, Martínez-Reyes F, Pérez-Meza M, Jaramillo L, Quinto R, Cueva P, Yépez J, Torres-Cintrón C, Tortolero-Luna G, Alonso R, Barrios E, Nikiforuk C, Shack L, Coldman A, Woods R, Noonan G, Turner D, Kumar E, Zhang B, McCrate F, Ryan S, Hannah H, Dewar R, MacIntyre M, Lalany A, Ruta M, Marrett L, Nishri D, McClure C, Vriends K, Bertrand C, Louchini R, Robb K, Stuart-Panko H, Demers S, Wright S, George J, Shen X, Brockhouse J, O'Brien D, Ward K, Almon L, Bates J, Rycroft R, Mueller L, Phillips C, Brown H, Cromartie B, Schwartz A, Vigneau F, MacKinnon J, Wohler B, Bayakly A, Clarke C, Glaser S, West D, Green M, Hernandez B, Johnson C, Jozwik D, Charlton M, Lynch C, Huang B, Tucker T, Deapen D, Liu L, Hsieh M, Wu X, Stern K, Gershman S, Knowlton R, Alverson J, Copeland G, Rogers D, Lemons D, Williamson L, Hood M, Hosain G, Rees J, Pawlish K, Stroup A, Key C, Wiggins C, Kahn A, Schymura M, Leung G, Rao C, Giljahn L, Warther B, Pate A, Patil M, Schubert S, Rubertone J, Slack S, Fulton J, Rousseau D, Janes T, Schwartz S, Bolick S, Hurley D, Richards J, Whiteside M, Nogueira L, Herget K, Sweeney C, Martin J, Wang S, Harrelson D, Keitheri Cheteri M, Farley S, Hudson A, Borchers R, Stephenson L, Espinoza J, Weir H, Edwards B, Wang N, Yang L, Chen J, Song G, Gu X, Zhang P, Ge H, Zhao D, Zhang J, Zhu F, Tang J, Shen Y, Wang J, Li Q, Yang X, Dong J, Li W, Cheng L, Chen J, Huang Q, Huang S, Guo G, Wei K, Chen W, Zeng H, Demetriou A, Pavlou P, Mang W, Ngan K, Swaminathan R, Kataki A, Krishnatreya M, Jayalekshmi P, Sebastian P, Sapkota S, Verma Y, Nandakumar A, Suzanna E, Keinan-Boker L, Silverman B, Ito H, Nakagawa H, Hattori M, Kaizaki Y, Sugiyama H, Utada M, Katayama K, Narimatsu H, Kanemura S, Koike T, Miyashiro I, Yoshii M, Oki I, Shibata A, Matsuda T, Nimri O, Ab Manan A, Bhoo-Pathy N, Tuvshingerel S, Chimedsuren O, Al Khater A, El Mistiri M, Al-Eid H, Jung K, Won Y, Chiang C, Lai M, Suwanrungruang K, Wiangnon S, Daoprasert K, Pongnikorn D, Geater S, Sriplung H, Eser S, Yakut C, Hackl M, Mühlböck H, Oberaigner W, Zborovskaya A, Aleinikova O, Henau K, Van Eycken L, Dimitrova N, Valerianova Z, Šekerija M, Zvolský M, Engholm G, Storm H, Innos K, Mägi M, Malila N, Seppä K, Jégu J, Velten M, Cornet E, Troussard X, Bouvier A, Faivre J, Guizard A, Bouvier V, Launoy G, Arveux P, Maynadié M, Mounier M, Fournier E, Woronoff A, Daoulas M, Clavel J, Le Guyader-Peyrou S, Monnereau A, Trétarre B, Colonna M, Cowppli-Bony A, Molinié F, Bara S, Degré D, Ganry O, Lapôtre-Ledoux B, Grosclaude P, Estève J, Bray F, Piñeros M, Sassi F, Stabenow R, Eberle A, Erb C, Nennecke A, Kieschke J, Sirri E, Kajueter H, Emrich K, Zeissig S, Holleczek B, Eisemann N, Katalinic A, Brenner H, Asquez R, Kumar V, Ólafsdóttir E, Tryggvadóttir L, Comber H, Walsh P, Sundseth H, Devigili E, Mazzoleni G, Giacomin A, Bella F, Castaing M, Sutera A, Gola G, Ferretti S, Serraino D, Zucchetto A, Lillini R, Vercelli M, Busco S, Pannozzo F, Vitarelli S, Ricci P, Pascucci C, Autelitano M, Cirilli C, Federico M, Fusco M, Vitale M, Usala M, Cusimano R, Mazzucco W, Michiara M, Sgargi P, Maule M, Sacerdote C, Tumino R, Di Felice E, Vicentini M, Falcini F, Cremone L, Budroni M, Cesaraccio R, Contrino M, Tisano F, Fanetti A, Maspero S, Candela G, Scuderi T, Gentilini M, Piffer S, Rosso S, Sacchetto L, Caldarella A, La Rosa F, Stracci F, Contiero P, Tagliabue G, Dei Tos A, Zorzi M, Zanetti R, Baili P, Berrino F, Gatta G, Sant M, Capocaccia R, De Angelis R, Liepina E, Maurina A, Smailyte G, Agius D, Calleja N, Siesling S, Visser O, Larønningen S, Møller B, Dyzmann-Sroka A, Trojanowski M, Góźdż S, Mężyk R, Grądalska-Lampart M, Radziszewska A, Didkowska J, Wojciechowska U, Błaszczyk J, Kępska K, Bielska-Lasota M, Kwiatkowska K, Forjaz G, Rego R, Bastos J, Silva M, Antunes L, Bento M, Mayer-da-Silva A, Miranda A, Coza D, Todescu A, Valkov M, Adamcik J, Safaei Diba C, Primic-Žakelj M, Žagar T, Stare J, Almar E, Mateos A, Quirós J, Bidaurrazaga J, Larrañaga N, Díaz García J, Marcos A, Marcos-Gragera R, Vilardell Gil M, Molina E, Sánchez M, Franch Sureda P, Ramos Montserrat M, Chirlaque M, Navarro C, Ardanaz E, Moreno-Iribas C, Fernández-Delgado R, Peris-Bonet R, Galceran J, Khan S, Lambe M, Camey B, Bouchardy C, Usel M, Ess S, Herrmann C, Bulliard J, Maspoli-Conconi M, Frick H, Kuehni C, Schindler M, Bordoni A, Spitale A, Chiolero A, Konzelmann I, Dehler S, Matthes K, Rashbass J, Stiller C, Fitzpatrick D, Gavin A, Bannon F, Black R, Brewster D, Huws D, White C, Finan P, Allemani C, Bonaventure A, Carreira H, Coleman M, Di Carlo V, Harewood R, Liu K, Matz M, Montel L, Nikšić M, Rachet B, Sanz N, Spika D, Stephens R, Peake M, Chalker E, Newman L, Baker D, Soeberg M, Aitken J, Scott C, Stokes B, Venn A, Farrugia H, Giles G, Threlfall T, Currow D, You H, Hendrix J, Lewis C. Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413]. Gynecol Oncol 2017; 147:726. [DOI: 10.1016/j.ygyno.2017.06.032] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
35
|
Fazio I, Mazzonello A, Macchiarella V, Testa L, La Paglia L, Federico M, Bruno T, Spada M, Oliveri D. Could Whole Body MRI Change Staging for Patients Affected by High Risk Prostate Cancer Candidate to Local Radiation Therapy? Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
36
|
Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MHJ, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol 2017; 28:1436-1447. [PMID: 28379322 PMCID: PMC5834038 DOI: 10.1093/annonc/mdx097] [Citation(s) in RCA: 200] [Impact Index Per Article: 28.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2017] [Indexed: 12/20/2022] Open
Abstract
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Collapse
Affiliation(s)
| | - P. Hilden
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B. Coiffier
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - A. Hagenbeek
- Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - G. Salles
- Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France
| | - W. Wilson
- Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA
| | - J. F. Seymour
- Peter MacCallum Cancer Centre and University of Melbourne, Australia
| | - K. Kelly
- Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA
| | - J. Gribben
- Department of Haemato-Oncology, Barts Cancer Institute, London, UK
| | - M. Pfreunschuh
- Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany
| | - F. Morschhauser
- Department of Hematology, Université de Lille 2, Lille, France
| | - H. Schoder
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | | | - J. Rademaker
- Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York
| | - R. Advani
- Department of Oncology, Stanford University, Stanford
| | | | | | | | - L. H. Sehn
- British Columbia Cancer Agency, Vancouver, Canada
| | - A. Engert
- Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany
| | | | - P.-L. Zinzani
- Department of Hematology, University of Bologna, Bologna
| | - M. Federico
- Department of Diagnostic Medicine, University of Modena, Modena, Italy
| | - M. Hutchings
- Department of Hematology, University of Copenhagen, Denmark
| | - C. Bollard
- Children’s National Health System, Washington, USA
| | - M. Trneny
- Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic
| | | | - K. Tobinai
- Department of Hematology, National Cancer Center Hospital, Tokyo, Japan
| | - J. S. Abramson
- Massachusetts General Hospital, Center for Lymphoma, Boston
| | - N. Fowler
- U.T. M.D.Anderson Cancer Center, Houston
| | - A. Goy
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
| | - M. Smith
- Cleveland Clinic, Cleveland, USA
| | | | - J. Kuruvilla
- Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada
| | - M. Dreyling
- Medicine Clinic III, Ludwig Maximilian University, Munich, Germany
| | | | - R. F. Little
- Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA
| | - I. Aurer
- Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia
| | | | | | - A. Gopal
- Fred Hutchinson Cancer Research Center, Seattle, USA
| | - S. Rule
- Haematology Department, Plymouth University, UK
| | | | - I. Kloos
- Servier, Neuilly sur Seine, France
| | - M. S. Kaminski
- University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
| | - M. Meignan
- Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France
| | - L. H. Schwartz
- Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York
| | - J. P. Leonard
- Weill Cornell Medicine and and New York Presbyterian Hospital, New York
| | - S. J. Schuster
- University of Pennsylvania School of Medicine, Philadelphia, USA
| | - V. E. Seshan
- Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| |
Collapse
|
37
|
Trotman J, Fosså A, Federico M, Stevens L, Kirkwood A, Clifton-Hadley L, Patrick P, Berkahn L, D'Amore F, Enblad G, Luminari S, Radford J, Barrington S, Johnson P. RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER a NEGATIVE INTERIM PET SCAN (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2437_53] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- J. Trotman
- Haematology, Concord Repatriation General Hospital; University of Sydney; Concord Australia
| | - A. Fosså
- Medical Oncology; Oslo University Hospital; Oslo Norway
| | - M. Federico
- Diagnostic Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Missouri Italy
| | - L. Stevens
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - A. Kirkwood
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - L. Clifton-Hadley
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - P. Patrick
- Cancer Trials Centre; Cancer Research UK and University College London; London UK
| | - L. Berkahn
- Haematology; Auckland City Hospital; Auckland New Zealand
| | - F. D'Amore
- Haematology; Aarhus University Hospital; Aarhus C Denmark
| | - G. Enblad
- Immunology, Genetics and Pathology; Uppsala University; Uppsala Sweden
| | - S. Luminari
- Arcispedale Santa Maria Nuova; Istituti di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - J. Radford
- Medical Oncology; Christie Hospital; Manchester UK
| | - S.F. Barrington
- The PET Imaging Centre, King's College London; King's Health Partners, St. Thomas' Hospital; London UK
| | - P. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
38
|
Luminari S, Marcheselli L, Manni M, Anastasia A, Vitolo U, Chiarenza A, Rigacci L, Angelucci E, Fama A, Pulsoni A, Rattotti S, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri A, Tarantino V, Bellei M, Federico M. POD24 AND CR30 ARE PROMISING SURROGATE ENDPOINTS FOR ASSESSING THE OUTCOME OF PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA ENROLLED IN THE FOLL05 TRIAL BY FIL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_91] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. Luminari
- Hematology; Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Anastasia
- Department of Hematology, ASST-Spedali Civili di Brescia; Brescia Italy
| | - U. Vitolo
- Hematology Unit; Città della Salute e della Scienza University and Hospital; Torino Italy
| | - A. Chiarenza
- Division of Hematology, AOU "Policlinico-Vittorio Emanuele"; University of Catania; Catania Italy
| | - L. Rigacci
- Hematology; University of Florence; Florence Italy
| | - E. Angelucci
- U.O. Ematologia, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro; Genoa Italy
| | - A. Fama
- Hematology Department, Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - A. Pulsoni
- Department of Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - S. Rattotti
- Department of Hematology-Oncology, Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - F. Angrilli
- Department of Hematology; Transfusion Medicine and Biotechnology, Spirito Santo Hospital; Pescara Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont, Division of Hematology; Novara Italy
| | - C. Stelitano
- Division of Hematology, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli; Reggio Calabria Italy
| | - G. Bertoldero
- U O di Oncologia ed Ematologia Oncologica, Ospedale di Mirano; Mirano Italy
| | - N. Cascavilla
- Division of Hematology; IRCCS “Casa Sollievo della Sofferenza” Hospital; San Giovanni Rotondo Italy
| | - F. Salvi
- Department Hematology, Ospedale SS Antonio e Biagio; Alessandria Italy
| | - A.J. Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Haematology; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Bellei
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
39
|
Luminari S, Tarantino V, Anastasia A, Boccomini C, Chiarenza A, Rigacci L, Angelucci E, Ferrari A, Pulsoni A, Rattotti S, Angrilli F, Gaidano G, Stelitano C, Bertoldero G, Cascavilla N, Salvi F, Ferreri A, Vallisa D, Balzarotti M, Cox M, Freilone R, Marcheselli L, Dondi A, Manni M, Federico M. LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_14] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- S. Luminari
- Hematology Unit; Azienda Ospedaliera Arcispedale Santa Maria Nuova-IRCCS; Reggio Emilia Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Anastasia
- Department of Hematology; ASST-Spedali Civili di Brescia; Brescia Italy
| | - C. Boccomini
- Hematology Unit; Città della Salute e della Scienza University and Hospital; Torino Italy
| | - A. Chiarenza
- Division of Hematology, AOU "Policlinico-Vittorio Emanuele"; University of Catania; Catania Italy
| | - L. Rigacci
- Hematology; University of Florence; Florence Italy
| | - E. Angelucci
- U.O. Ematologia; IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro; Genoa Italy
| | - A. Ferrari
- Hematology Unit, Arcispedale Santa Maria Nuova; IRCCS of Reggio Emilia; Reggio Emilia Italy
| | - A. Pulsoni
- Department of Cellular Biotechnologies and Hematology; Sapienza University of Rome; Rome Italy
| | - S. Rattotti
- Department of Hematology-Oncology; Fondazione IRCCS Policlinico San Matteo; Pavia Italy
| | - F. Angrilli
- Department of Hematology; Transfusion Medicine and Biotechnology, Spirito Santo Hospital; Pescara Italy
| | - G. Gaidano
- Department of Translational Medicine; University of Eastern Piedmont., University of Eastern Piedmont, Division of Hematology; Novara Italy
| | - C. Stelitano
- Division of Hematology; Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli; Reggio Calabria Italy
| | - G. Bertoldero
- U O di Oncologia ed Ematologia Oncologica; Ospedale di Mirano; Mirano Italy
| | - N. Cascavilla
- Division of Hematology; IRCCS "Casa Sollievo della Sofferenza" Hospital; San Giovanni Rotondo Italy
| | - F. Salvi
- Department Hematology; Ospedale SS Antonio e Biagio; Alessandria Italy
| | - A.J. Ferreri
- Unit of Lymphoid Malignancies, Department of Onco-Haematology; IRCCS San Raffaele Scientific Institute; Milan Italy
| | - D. Vallisa
- Department of Hematology; Guglielmo da Saliceto Hospital; Piacenza Italy
| | - M. Balzarotti
- Hematology; IRCCS Humanitas Cancer Center; Rozzano, Milano Italy
| | - M.C. Cox
- Hematology Unit; Sant'andrea Hospital; Rome Italy
| | - R. Freilone
- Hematology Unit, Department of Medicine; ASLT04 Piedmont, Ivrea- Ciriè-Chivasso; Italy
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - A. Dondi
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| |
Collapse
|
40
|
Federico M, Caballero D, Marcheselli L, Tarantino V, Sarkozy C, Lopez Guillermo A, Wondergem M, Kimby E, Rusconi C, Zucca E, Montoto S, da Silva M, Aurer I, Paszkiewicz-Kozik E, Cartron G, Morschhauser F, Alcoceba M, Chamuleau M, Lockmer S, Minoia C, Issa D, Alonso S, Conte L, Salles G, Coiffier B. THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB: THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_104] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - D. Caballero
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Marcheselli
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - V. Tarantino
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena e Reggio Emilia; Modena Italy
| | - C. Sarkozy
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - A. Lopez Guillermo
- Department of Hematology; Hospital Clinic, IDIBAPS, CIBERONC; Barcelona Spain
| | - M. Wondergem
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - E. Kimby
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Rusconi
- Division of Hematology; Niguarda Hospital; Milan Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland; Ospedale San Giovanni; Bellinzona Switzerland
| | - S. Montoto
- Department of Hematology; Barts Cancer Institute, QMUL; London UK
| | - M.G. da Silva
- Department of Hematology; Instituto Português de Oncologia de Lisboa; Lisbon Portugal
| | - I. Aurer
- Division of Hematology; University Hospital Centre Zagreb; Zagreb Croatia
| | - E. Paszkiewicz-Kozik
- Department of Lymphoid Malignancies; The Maria Sklodowska-Curie Memorial Institute and Oncology Centre; Warszawa Poland
| | - G. Cartron
- Department of Hematology; CHU Montpellier; Montpellier France
| | - F. Morschhauser
- Department of Clinical Hematology, CHU Lille, Unite GRITA; Universite de Lille 2; Lille France
| | - M. Alcoceba
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - M. Chamuleau
- Department of Hematology; VU University Medical Center; Amsterdam Netherlands
| | - S. Lockmer
- Department of Hematology; Karolinska Institute; Stockholm Sweden
| | - C. Minoia
- Haematology Unit, National Cancer Research Centre; Istituto Tumori "Giovanni Paolo II"; Bari Italy
| | - D. Issa
- Department of Hematology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch; Netherlands
| | - S. Alonso
- Department of Hematology; Hospital Universitario de Salamanca; Salamanca Spain
| | - L. Conte
- Interdisciplinary Laboratory of Applied Research in Medicine (DReAM); University of Salento; Lecce Italy
| | - G. Salles
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| | - B. Coiffier
- Department of Hematology, Hospices Civils de Lyon; Universite Claude Bernard Lyon-1Pierre Bénite Cedex; France
| |
Collapse
|
41
|
Fox C, Bellei M, Manni M, Kim S, Ko Y, Shustov A, Cabrera M, Chiattone C, Horwitz S, Spina M, Advani R, Angrilli F, De Souza C, Dlouhy I, Fernandez-Alvarez R, Gabús R, Hitz F, Laszlo D, Montoto S, Nagler A, Pavlovsky A, Vitolo U, Zoppegno L, Federico M, Kim W. IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- C.P. Fox
- Nottingham University Hospitals NHS Trust, and Institute of Cancer Sciences, University of Birmingham; Nottingham UK
| | - M. Bellei
- Dept. Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Manni
- Dept. Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - S.J. Kim
- Division of Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| | - Y.H. Ko
- Department of Pathology; Sungkyunkwan University; Seoul Republic of Korea
| | - A.R. Shustov
- Division of Hematology, FHCRC; University of Washington Medical Center; Seattle USA
| | - M.E. Cabrera
- Sección Hematología, Hospital del Salvador; Universidad de Chile; Santiago de Chile Chile
| | - C.S. Chiattone
- Departamento de Clínica Médica, FCM da Santa Casa de São Paulo; Centro de Linfomas Núcleo de Oncologia Hospital Samaritano; São Paulo Brazil
| | - S.M. Horwitz
- Dept. Medicine; Memorial Sloan-Kettering Cancer Center; New York USA
| | - M. Spina
- Medical Oncology A; Aviano National Cancer Institute; Aviano Italy
| | - R.H. Advani
- Division of Oncology; Stanford University School of Medicine; Stanford USA
| | - F. Angrilli
- Dip. Ematologia, Medicina Trasfusionale e Biotecnologie; UOSD Centro Diagnosi e Terapia Linfomi; PO Pescara, Pescara Italy
| | - C.A. De Souza
- Departamento de Clínica Médica; Universidade Estadual de Campinas; Campinas Brazil
| | - I. Dlouhy
- Hematology Department; Hospital Clinic; Barcelona Italy
| | | | - R. Gabús
- Service of Hematology and Bone Marrow Transplantation; Hospital Maciel; Montevideo Uruguay
| | - F. Hitz
- Department of Oncology/Haematology; Cantonal Hospital; St Gallen Switzerland
| | - D. Laszlo
- Division of Haemato-Oncology; IEO - Istituto Europeo di Oncologia; Milan Italy
| | - S. Montoto
- Department of Haematology; Barts Health NHS Trust; London Italy
| | - A. Nagler
- Department of Bone Marrow Transplantation; Tel-Aviv University; Tel-Aviv Israel
| | | | - U. Vitolo
- S.C. Ematologia, Dipartimento di Oncologia ed Ematologia, S.C. Ematologia, Dipartimento di Oncologia ed Ematologia; Torino Italy
| | - L. Zoppegno
- Hematologia, Hospital provincial San Martín de La Plata; Buenos Aires Argentina
| | - M. Federico
- Dept. Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - W.S. Kim
- Division of Hematology-Oncology; Samsung Medical Center; Seoul Republic of Korea
| |
Collapse
|
42
|
Ferrero S, Genuardi E, Klous P, Drandi D, Mantoan B, Monitillo L, Barbero D, Yilmaz M, Cattellino F, Vasta M, Cavallo F, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, Splinter E, Ladetto M. NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S. Ferrero
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - E. Genuardi
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - P. Klous
- B.V., Cergentis B.V.; Utrecht Netherlands
| | - D. Drandi
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - B. Mantoan
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - L. Monitillo
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - D. Barbero
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - M. Yilmaz
- B.V., Cergentis B.V.; Utrecht Netherlands
| | - F. Cattellino
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - M. Vasta
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - F. Cavallo
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | - S. Cortelazzo
- Oncology Unit; Humanitas/Gavazzeni Clinic; Bergamo Italy
| | - U. Vitolo
- Department of Oncology, Division of Hematology; AOU Città della Salute e della Scienza di Torino; Torino Italy
| | - S. Luminari
- Clinics and Public Health, “Arcispedale S.Maria Nuova”; University of Modena e Reggio Emilia, Hematology Division, Department of Diagnostic Medicine; Reggio Emilia Italy
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Boccadoro
- Department of Molecular Biotechnology and Health Sciences; University of Torino; Torino Italy
| | | | - M. Ladetto
- Division of Hematology; Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo; Alessandria Italy
| |
Collapse
|
43
|
Preston A, Kirkwood A, Federico M, Trotman J, Fossa A, Stevens L, Clifton-Hadley L, Patrick P, Berkahn L, d'Amore F, Enblad G, Luminari S, Radford J, Johnson P. OUTCOMES OF TREATMENT FOR OBESE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN THE RATHL TRIAL (CRUK/07/033). Hematol Oncol 2017. [DOI: 10.1002/hon.2438_31] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- A. Preston
- Pharmacy; University Hospitals Bristol; Bristol UK
| | - A. Kirkwood
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - M. Federico
- Diagnostic Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - J. Trotman
- Haematology, Concord Repatriation General Hospital; University of Sydney; Concord Australia
| | - A. Fossa
- Medical Oncology; Oslo University Hospital; Oslo Norway
| | - L. Stevens
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - L. Clifton-Hadley
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - P. Patrick
- Cancer Research UK & UCL Cancer Trials Centre; University College London; London UK
| | - L. Berkahn
- Haematology; Auckland City Hospital; Auckland New Zealand
| | - F. d'Amore
- Haematology; Aarhus University Hospital; Aarhus C Denmark
| | - G. Enblad
- Immunology, Genetics and Pathology; Uppsala University; Uppsala Sweden
| | - S. Luminari
- Arcispedale Santa Maria Nuova; Istituti di Ricovero e Cura a Carattere Scientifico; Reggio Emilia Italy
| | - J. Radford
- Medical Oncology; Christie Hospital; Manchester UK
| | - P.W. Johnson
- Cancer Research UK Centre; University of Southampton; Southampton UK
| |
Collapse
|
44
|
Cottereau A, Versari A, Loft A, Casasnovas R, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Girinsky T, Van Zele E, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M, Meignan M. PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_16] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Cottereau
- Nuclear Medicine department; Tenon Hospital; Paris France
| | - A. Versari
- Nuclear Medicine; Arcispedale Santa Maria Nuova - IRCCS; Reggio Emilia Italy
| | - A. Loft
- Dep. of Clinical Physiology, Nuclear Medicine, Rigshospitalet; Copenhagen University Hospital; Copenhagen Denmark
| | - R. Casasnovas
- Hematology; CHU le Bocage, and INSERM, LNC URM866; Dijon France
| | - M. Bellei
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - R. Ricci
- LYSA Imaging, LYSARC; Henri Mondor Hospital; Creteil France
| | - S. Bardet
- Nuclear Medicine; CLCC François Baclesse; Caen France
| | - A. Castagnoli
- Nuclear Medicine; Ospedale Santo Stefano; Prato Italy
| | - P. Brice
- Hematology; Saint-Louis Hospital, APHP; Paris France
| | - J. Raemaekers
- Hematology; Radboud University Medical Cente; Nijmegen Netherlands
| | - B. Deau
- Hematology; Cochin Hospital, APHP; Paris France
| | - C. Fortpied
- Statistics; European Organization for Research and Treatment of Cancer; Brussels Belgium
| | - T. Raveloarivahy
- Hematology; European Organisation for Research and Treatment of Cancer; Brussels Belgium
| | - T. Girinsky
- Radiation oncology; Institut Gustave Roussy; Villejuif France
| | - E. Van Zele
- LYSA Imaging, LYSARC; Henri Mondor Hospital; Creteil France
| | - T. Vander Borght
- Nuclear Medicine; Université Catholique de Louvain IMRE/MINT CHU Mont-Godinne; Yvoir Belgium
| | - M. Federico
- Department of Diagnostic, Clinical and Public Health Medicine; University of Modena and Reggio Emilia; Modena Italy
| | - M. Hutchings
- Hematology Department, Rigshospitalet; Copenhagen University Hospital; Copenhagen Denmark
| | - U. Ricardi
- Oncology; AO Città della Salute e della Scienza; Torino Italy
| | - M. Andre
- Hematology; Université catholique de Louvain, CHU UCL Namur; Yvoir Belgium
| | - M. Meignan
- LYSA Imaging; Henri Mondor University Hospitals; Creteil France
| |
Collapse
|
45
|
Cottereau A, Versari A, Dupuis J, Chartier L, Menga M, Casasnovas R, Haioun C, Tilly H, Tarantino V, Dubreuil J, Federico M, Salles G, Luminari S, Trotman J, Meignan M. PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: a POOLED ANALYSIS FROM LYSA AND FIL TRIALS. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_105] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- A. Cottereau
- Nuclear Medicine Department; Tenon Hospital; Paris France
| | - A. Versari
- Nuclear Medicine Department; Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - J. Dupuis
- Hematology Department, Lymphoid Malignancies Unit; Henri Mondor Hospital; Créteil France
| | - L. Chartier
- Department of Biostatistics; Centre Hospitalier Lyon Sud, Pierre Bénite, LYSARC; Pierre-Bénite France
| | - M. Menga
- Nuclear Medicine Department; Santa Maria Nuova Hospital; Reggio Emilia Italy
| | | | - C. Haioun
- Hematology Department, Lymphoid Malignancies Unit; Henri Mondor Hospital; Créteil France
| | - H. Tilly
- Hematology Department, UMR918, Centre Henri Becquerel; Université de Rouen; Rouen France
| | - V. Tarantino
- Nuclear Medicine Department; Santa Maria Nuova Hospital; Reggio Emilia Italy
| | - J. Dubreuil
- Nuclear Medicine Department, Centre Hospitalier Lyon Sud, Pierre Bénite; Pierre Benite France
| | - M. Federico
- Hematology; University of Modena and Reggio Emilia; Modena Italy
| | - G. Salles
- Hematology Department; Hospices Civils de Lyon 1, Université Claude Bernard Lyon 1; Pierre Benite France
| | - S. Luminari
- Hematology Department, Santa Maria Nuova Hospital, IRCCS; University of Modena and Reggio Emilia; Modena Italy
| | - J. Trotman
- Haematology Department, Concord Hospital; University of Sydney; Sydney Australia
| | - M. Meignan
- LYSA Imaging; Henri Mondor University Hospitals; Creteil France
| |
Collapse
|
46
|
Federico M, Tornero A, Torres S, Pinar B, Rey Baltar M, Lloret M, Lara P. OC-0367: Dose-response curve for vaginal stenosis. Final results of a prospective study. Radiother Oncol 2017. [DOI: 10.1016/s0167-8140(17)30809-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
47
|
Federico M. European Hematology Association - 22nd Annual Congress. Madrid, Spain - June 22-25, 2017. DRUG FUTURE 2017. [DOI: 10.1358/dof.2017.042.08.2676118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Santi RM, Ceccarelli M, Catania G, Monagheddu C, Evangelista A, Bernocco E, Monaco F, Federico M, Vitolo U, Cortelazzo S, Cabras MG, Spina M, Baldini L, Boccomini C, Chiappella A, Bari A, Luminari S, Calabrese M, Levis A, Visco C, Contino L, Ciccone G, Ladetto M. PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Res 2016; 140 Suppl 1:S177. [PMID: 27161692 DOI: 10.1016/s0049-3848(16)30136-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Recent studies show that the risk of VTE in NHL pts is similar to that observed in high risk solid tumors (i.e. pancreatic, ovarian cancer). VTE in NHL occurs in most cases within three months from diagnosis and can have substantial impact on treatment delivery and outcome as well as on quality of life. However few data are available on potential predictors. AIMS To better clarify the epidemiology of early (within six months from treatment start) VTE in NHL we conducted a pooled data analysis of 12 clinical trials from FIL. Our analysis included basic demographic features, lymphoma-related characteristics as well the Khorana score (based on histology, BMI, platelets WBC and HB counts) which is extensively used in solid tumors to predict VTE risk. PATIENTS AND METHODS From Jan. 2010 to Dec. 2014, all pts with B-cell NHL enrolled in prospective clinical trials from FIL for frontline treatment were included. For 9 studies study period included the entire trial population was included. The analyses were conducted based on CRFs as well as pharmacovigilance reports. VTE definition and grading was stated according to standard criteria of toxicity (CTCAE V4.0). Cumulative incidence of VTE from the study enrollment was estimated using the method described by Gooley et al. accounting for death from any causes as a competing risk. The Fine & Gray survival model was used to identify predictors of VTE among NHL pts. Factors predicting the grade of VTE were investigated using an ordinal logistic regression model. This pooled data analysis was approved by local IRB. RESULTS Overall, 1,717 patients belonging to 12 studies were evaluated. Eight were phase I/II or II (25% of pts) and 4 phase III (75% of pts). M/F ratio was 1.41, Median age was 57, (IQ range (IQR) 49-66). Histologies were: DLCL-B 34%, FL 41%, MCL 18%, other 6%. Median BMI was 25 (IQR 22-28). Median Hb, WBC and platelets counts were 13g/dl) (IQR 11.5-14.2), 7.1*10^(9)/l (IQR 5.6-10.3), 224*10^(9)/l (IQR 169-298), respectively. 1189 pts were evaluable Khorana score: 58% low risk, 30% intermediate risk, 12% were high risk. Human erythropoetin support was given to 9% of patients. All pts received Rituximab. Planned therapeutic programs included ASCT in 27% of pts, conventional chemotherapy in 67% a conventional chemotherapy plus lenalidomide in 6%. Overall 59 any grade VTE episodes occurred in 51 pts (2.9%), including 21 grade III-IV VTE (18 pts). None was fatal. Median time from study enrolment to VTE was 63 days (IQR: 35-110). Considering death as a competitive event the 6 months cumulative incidence of VTE was 2,2% in low risk Khorana score, 4.5% (95%IC: 2.3-6.7) in intermediate and 6.6% (95%IC: 2.4-10.8) in high risk (p=0.012) (figure 1). Khorana score was predictive also for grade III-IV events as they were 0,7% (95% CI:0.1-1.4) in low risk and 2.0% (95% CI:0.8-3.3) in intermediate-high risk (p=0.048). The results were similar also after excluding lenalidomide containing studies. The Fine and Gray multivariate analyses, adjusted for age and stage, showed that Khorana score (intermediate risk adjHR=1.96; 95%IC: 0.84-4.56 and high risk adjHR=3.81; 95%IC: 1.51-9.58) and DLCL-B histotype (adjHR=2.58; 95% CI: 1.01-6.55) were independently associated to an increased risk of VTE. Moreover an ordinal logistical regression model indicated that the increase of one point in the Khorana score resulted in an increased risk of VTE (OR=1.85; 95% CI: 1.23-2.79). CONCLUSIONS Our results suggest that DLCL-B histotype and Khorana score are predictors of VTE in NHL. The latter might become a simple and effective tool to assess the risk of VTE in NHL. Prospective validation including also patients not eligible for clinical trials is needed.
Collapse
Affiliation(s)
| | - M Ceccarelli
- SCDU Epidemiologia dei Tumori-CPO Piemonte, Torino
| | - G Catania
- Division of Hematology, Az Osp SS Antinio e Biagio e Cesare Arrigo, Alessandria
| | - C Monagheddu
- SCDU Epidemiologia dei Tumori-CPO Piemonte, Torino
| | - A Evangelista
- Unit of Cancer Epidemiology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza, Torino
| | - E Bernocco
- Division of Haematology - SS. Antonio e Biagio e Cesare Arrigo Hospital, Alessandrio
| | - F Monaco
- Division of Hematology, AZ Osp SS Antonio e Biagio e Cesare Arrigo, Alessandria
| | - M Federico
- Oncologia Medica, Università di Modena e Reggio Emilia, Modena
| | - U Vitolo
- Hematology II, Azienda Ospedaliera Città della Salute, Torino
| | - S Cortelazzo
- Department of Haematology and Bone Marrow Transplantation, Regional Hospital, S. Maurizio, Bolzano/Bozen
| | - M G Cabras
- Division of Hematology, Ospedale Businco, Cagliari
| | - M Spina
- Division of Hematology, IRCCS CRO Aviano
| | - L Baldini
- Division of Hematology, Fondazione IRCCS Ospedale Maggiore Policlinico, Università degli Studi di Milano
| | - C Boccomini
- Division of Hematology II, AOU Citta della Salute e della Scienza, Torino
| | - A Chiappella
- Department of Hematology, Azienda Ospedaliera Città della Salute e della Scienza, Torino
| | - A Bari
- Program of Innovative Therapy in Oncology and Hematology, Department of Diagnostic, Clinical and Public Health Medicine University of Modena and Reggio Emilia, Modena
| | - S Luminari
- Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena
| | - M Calabrese
- Fondazione Italiana Linfomi Onlus, Alessandria
| | - A Levis
- Italian Lymphoma Foundation (FIL), Alessandria
| | | | | | - G Ciccone
- SCDU Epidemiologia dei Tumori-CPO Piemonte, Az Osp Citta della salute e della Scienza, Torino
| | - M Ladetto
- Division of Hematology, Az Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria; Italy
| |
Collapse
|
49
|
Gentile M, Shanafelt TD, Cutrona G, Molica S, Tripepi G, Alvarez I, Mauro FR, Di Renzo N, Di Raimondo F, Vincelli I, Todoerti K, Matis S, Musolino C, Fabris S, Vigna E, Levato L, Zupo S, Angrilli F, Consoli U, Festini G, Longo G, Cortelezzi A, Arcari A, Federico M, Mannina D, Recchia AG, Neri A, Kay NE, Ferrarini M, Morabito F. A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia 2015; 30:1440-3. [PMID: 26648537 DOI: 10.1038/leu.2015.333] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- M Gentile
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
| | - T D Shanafelt
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - G Cutrona
- Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica, SS Molecular Diagnostics IRCCS S. Martino-IST, Genova, Italy
| | - S Molica
- Department of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
| | - G Tripepi
- Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica, Reggio Calabria, Italy
| | - I Alvarez
- Division of Haematology, Dipartimento Oncologico e Tecnologie Avanzate, Arcispedale S. Maria Nuova/IRCCS, Reggio Emilia, Italy
| | - F R Mauro
- Divisione di Ematologia, Dipartimento di Biotecnologie Cellulari ed Ematologia, Università La Sapienza, Roma, Italy
| | - N Di Renzo
- Hematology Unit, Ospedale Vito Fazzi, Lecce, Italy
| | - F Di Raimondo
- Division of Haematology, Department of Biomedical Sciences, University of Catania and Ferrarotto Hospital, Catania, Italy
| | - I Vincelli
- Hematology Unit, Dipartimento di Onco-Ematologia, A.O. of Reggio Calabria, Reggio Calabria, Italy
| | - K Todoerti
- Laboratory of Preclinical and Translational Research, IRCCS, Referral Cancer Center of Basilicata, Rionero in Vulture, Dipartimento Onco-Ematologico, Potenza, Italy
| | - S Matis
- Direzione Scientifica IRCCS, San Martino IST, Genova, Italy
| | - C Musolino
- Division of Haematology, Dipartimento di Medicina Interna,University of Messina, Messina, Italy
| | - S Fabris
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - E Vigna
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy
| | - L Levato
- Department of Oncology and Haematology, Pugliese-Ciaccio Hospital, Catanzaro, Italy
| | - S Zupo
- Dipartimento di diagnostica della patologia e delle cure ad alta complessità tecnologica, SS Molecular Diagnostics IRCCS S. Martino-IST, Genova, Italy
| | - F Angrilli
- Department of Hematology, Ospedale Santo Spirito, Pescara, Italy
| | - U Consoli
- U.O.S. di Emato-Oncologia, Ospedale Garibaldi-Nesima, Catania, Italy
| | - G Festini
- Dipartimento ad Attività Integrata Oncologia, Centro di Riferimento Ematologico-Seconda Medicina, Azienda Ospedaliero-Universitaria, Ospedali Riuniti, Trieste, Italy
| | - G Longo
- Dipartimento di Oncologia, Unità di Ematologia, Ospedale San Vincenzo, Taormina, Italy
| | - A Cortelezzi
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - A Arcari
- Dipartimento di Oncologia ed Ematologia, Hematology Unit, Department of Onco-Hematology, Guglielmo da Saliceto Hospital, Piacenza, Italy
| | - M Federico
- Department of Onco-hematology, Università di Modena Centro Oncologico Modenese, Policlinico Modena, Italy
| | - D Mannina
- Divisione di Ematologia, Ospedale Papardo, Messina, Italy
| | - A G Recchia
- Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Cosenza, Italy
| | - A Neri
- Department of Clinical Sciences and Community Health, University of Milano and Hematology CTMO, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
| | - N E Kay
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA
| | - M Ferrarini
- Direzione Scientifica IRCCS, San Martino IST, Genova, Italy
| | - F Morabito
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.,Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, Aprigliano, Cosenza, Italy
| |
Collapse
|
50
|
Federico M, Tornero A, Pozas ST, Pinar B, Baltar Oramas DR, Lara P, Oliva RM. Correlation Between Vaginal Stenosis (VS), Vaginal Packing (VP) Volume, and Vaginal Dose in Cervical Cancer High-Dose-Rate Brachytherapy. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|